Is Arbutus Biopharma Corp (ABUS) a Buy, Sell, or Hold?
Arbutus Biopharma Corp
NASDAQ:ABUS
$4.61 USD
-$0.06 (-1.18%)
- Volume
- 1.69M
- Average Volume
- 2.15M
- Market Capitalization
- $910.65M
- P/E Ratio
- 5.53
- Dividend Yield
- 0.00%
- Price Target
- $8.50
- Year High
- $5.38
- Year Low
- $3.08
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $54.26
NUMBER OF INSIDERS BUYING (LAST 12 MONTHS)
20
NUMBER OF INSIDERS SELLING (LAST 12 MONTHS)
4
AMOUNT OF INSIDER SELLING (LAST 12 MONTHS)
$ 76654
ABUS Estimated and Actual Revenue by Quarter
Get MSFT Insider Trade Alerts
ABUS Insider Trading History
| Insider Name | Title | Date | Transaction | Cost | Filing Date |
|---|---|---|---|---|---|
| Sawhney Roger | director | 2026-06-08 | A-Award | 4.24 | 2026-06-10 |
| Beardsley Robert A | director | 2026-06-08 | A-Award | 4.24 | 2026-06-10 |
| Nguyen Tuan | officer: Chief Financial Officer | 2026-02-02 | A-Award | 4.39 | 2026-02-02 |
| Nguyen Tuan | officer: Chief Financial Officer | 2026-02-02 | A-Award | 0 | 2026-02-02 |
| Androski Lindsay | director, officer: President and CEO | 2026-02-02 | A-Award | 4.39 | 2026-02-02 |
| Androski Lindsay | director, officer: President and CEO | 2026-02-02 | A-Award | 0 | 2026-02-02 |
| Sawhney Roger | director | 2025-08-04 | A-Award | 3.34 | 2025-08-06 |
| Sawhney Roger | director: | 2025-08-04 | 0 | 2025-08-06 | |
| Nguyen Tuan | officer: Chief Financial Officer | 2025-03-31 | A-Award | 3.49 | 2025-04-01 |
| Nguyen Tuan | officer: Chief Financial Officer | 2025-03-31 | A-Award | 3.5 | 2025-03-31 |
| Nguyen Tuan | officer | 2025-03-28 | 0 | 2025-03-31 | |
| Hasija Anuj | director | 2025-03-18 | A-Award | 3.2 | 2025-03-20 |
| Beardsley Robert A | director | 2025-03-18 | A-Award | 3.2 | 2025-03-20 |
| Androski Lindsay | director, officer: President and CEO | 2025-03-18 | A-Award | 3.2 | 2025-03-20 |
| Hasija Anuj | director: | 2025-02-24 | 0 | 2025-03-06 | |
| Bishop Joseph E | director: | 2025-02-24 | 0 | 2025-03-06 | |
| Beardsley Robert A | director: | 2025-02-24 | 0 | 2025-03-06 | |
| Androski Lindsay | director, officer: President and CEO | 2025-02-24 | 0 | 2025-03-06 | |
| Gline Matthew | director, 10 percent owner: | 2025-02-24 | 0 | 2025-03-06 | |
| Naftzger J. Christopher | officer: General Counsel and CCO | 2025-02-14 | A-Award | 3.29 | 2025-02-19 |
| Naftzger J. Christopher | officer: General Counsel and CCO | 2025-02-14 | A-Award | 0 | 2025-02-19 |
| McElhaugh Michael J. | director, officer: Interim President & CEO | 2025-02-14 | A-Award | 0 | 2025-02-19 |
| McElhaugh Michael J. | director, officer: Interim President & CEO | 2025-02-14 | A-Award | 3.29 | 2025-02-19 |
| HASTINGS DAVID C | officer: Chief Financial Officer | 2025-02-14 | A-Award | 3.29 | 2025-02-19 |
| HASTINGS DAVID C | officer: Chief Financial Officer | 2025-02-14 | A-Award | 0 | 2025-02-19 |
| Sims Karen | officer: Chief Medical Officer | 2025-02-14 | A-Award | 3.29 | 2025-02-19 |
| Sims Karen | officer: Chief Medical Officer | 2025-02-14 | A-Award | 0 | 2025-02-19 |
| HASTINGS DAVID C | officer: Chief Financial Officer | 2025-02-04 | S-Sale | 3.283 | 2025-02-05 |
| Sims Karen | officer: Chief Medical Officer | 2025-02-04 | S-Sale | 3.283 | 2025-02-05 |
| McElhaugh Michael J. | director, officer: Interim President & CEO | 2025-02-04 | S-Sale | 3.283 | 2025-02-05 |
| Naftzger J. Christopher | officer: General Counsel and CCO | 2025-02-04 | S-Sale | 3.283 | 2025-02-05 |
| MANCHESTER KEITH S | director | 2024-08-14 | M-Exempt | 0.56 | 2024-08-16 |
| MANCHESTER KEITH S | director | 2024-08-14 | S-Sale | 3.6895 | 2024-08-16 |
| MANCHESTER KEITH S | director | 2024-08-14 | M-Exempt | 0.56 | 2024-08-16 |
| BURGESS DANIEL D | director | 2024-05-23 | A-Award | 3.28 | 2024-05-24 |
| MANCHESTER KEITH S | director | 2024-05-23 | A-Award | 3.28 | 2024-05-24 |
| HENRIQUES RICHARD C JR | director | 2024-05-23 | A-Award | 3.28 | 2024-05-24 |
| Meyers James R | director | 2024-05-23 | A-Award | 3.28 | 2024-05-24 |
| Rewolinski Melissa | director | 2024-05-23 | A-Award | 3.28 | 2024-05-24 |
| Torti Frank | director | 2024-05-23 | A-Award | 3.28 | 2024-05-24 |
| Naftzger J. Christopher | officer: General Counsel and CCO | 2024-02-01 | A-Award | 2.4 | 2024-02-05 |
| Naftzger J. Christopher | officer: General Counsel and CCO | 2024-02-01 | A-Award | 0 | 2024-02-05 |
| Sims Karen | officer: Chief Medical Officer | 2024-02-01 | A-Award | 2.4 | 2024-02-05 |
| Sims Karen | officer: Chief Medical Officer | 2024-02-01 | A-Award | 0 | 2024-02-05 |
| Sims Karen | officer: Chief Medical Officer | 2024-02-02 | S-Sale | 2.3125 | 2024-02-05 |
| HASTINGS DAVID C | officer: Chief Financial Officer | 2024-02-01 | A-Award | 2.4 | 2024-02-05 |
| HASTINGS DAVID C | officer: Chief Financial Officer | 2024-02-01 | A-Award | 0 | 2024-02-05 |
| HASTINGS DAVID C | officer: Chief Financial Officer | 2024-02-02 | S-Sale | 2.3125 | 2024-02-05 |
| Sofia Michael J. | officer: Chief Scientific Officer | 2024-02-01 | A-Award | 0 | 2024-02-05 |
| Sofia Michael J. | officer: Chief Scientific Officer | 2024-02-02 | S-Sale | 2.3125 | 2024-02-05 |
| Sofia Michael J. | officer: Chief Scientific Officer | 2024-02-01 | A-Award | 2.4 | 2024-02-05 |
| McElhaugh Michael J. | director, officer: Interim President & CEO | 2024-02-01 | A-Award | 0 | 2024-02-05 |
| McElhaugh Michael J. | director, officer: Interim President & CEO | 2024-02-02 | S-Sale | 2.3125 | 2024-02-05 |
| McElhaugh Michael J. | director, officer: Interim President & CEO | 2024-02-01 | A-Award | 2.4 | 2024-02-05 |
| Rewolinski Melissa | director | 2023-07-12 | A-Award | 2.27 | 2023-07-13 |
| Rewolinski Melissa | director: | 2023-07-12 | 0 | 2023-07-13 | |
| Sims Karen | officer: Chief Medical Officer | 2023-07-10 | A-Award | 2.26 | 2023-07-12 |
| Sims Karen | officer: Chief Medical Officer | 2023-07-10 | 0 | 2023-07-12 | |
| Sims Karen | officer: Chief Medical Officer | 2023-07-10 | 2.9 | 2023-07-12 | |
| Sims Karen | officer: Chief Medical Officer | 2023-07-10 | 4.57 | 2023-07-12 | |
| Sims Karen | officer: Chief Medical Officer | 2023-07-10 | 4.33 | 2023-07-12 | |
| Sims Karen | officer: Chief Medical Officer | 2023-07-10 | 5.2 | 2023-07-12 | |
| Sims Karen | officer: Chief Medical Officer | 2023-07-10 | 2.81 | 2023-07-12 | |
| Sims Karen | officer: Chief Medical Officer | 2023-07-10 | 3.35 | 2023-07-12 | |
| Sims Karen | officer: Chief Medical Officer | 2023-07-10 | 3.55 | 2023-07-12 | |
| Naftzger J. Christopher | officer: General Counsel and CCO | 2023-07-10 | A-Award | 2.26 | 2023-07-12 |
| Naftzger J. Christopher | officer | 2023-07-10 | 0 | 2023-07-12 | |
| HENRIQUES RICHARD C JR | director | 2023-05-24 | A-Award | 2.56 | 2023-05-26 |
| BURGESS DANIEL D | director | 2023-05-24 | A-Award | 2.56 | 2023-05-26 |
| MANCHESTER KEITH S | director | 2023-05-24 | A-Award | 2.56 | 2023-05-26 |
| Torti Frank | director | 2023-05-24 | A-Award | 2.56 | 2023-05-26 |
| Meyers James R | director | 2023-05-24 | A-Award | 2.56 | 2023-05-26 |
| McElhaugh Michael J. | officer: Chief Business Officer | 2023-02-01 | A-Award | 0 | 2023-02-03 |
| McElhaugh Michael J. | officer: Chief Business Officer | 2023-02-01 | A-Award | 2.9 | 2023-02-03 |
| Sofia Michael J. | officer: Chief Scientific Officer | 2023-02-01 | A-Award | 0 | 2023-02-03 |
| Sofia Michael J. | officer: Chief Scientific Officer | 2023-02-01 | A-Award | 2.9 | 2023-02-03 |
| HASTINGS DAVID C | officer: Chief Financial Officer | 2023-02-01 | A-Award | 2.9 | 2023-02-03 |
| HASTINGS DAVID C | officer: Chief Financial Officer | 2023-02-01 | A-Award | 0 | 2023-02-03 |
| Collier William H. | director, officer: President and CEO | 2023-02-01 | A-Award | 2.9 | 2023-02-03 |
| Collier William H. | director, officer: President and CEO | 2023-02-01 | A-Award | 0 | 2023-02-03 |
| Howard Elizabeth | officer: EVP, GC, Compliance | 2023-02-01 | A-Award | 2.9 | 2023-02-03 |
| Howard Elizabeth | officer: EVP, GC, Compliance | 2023-02-01 | A-Award | 0 | 2023-02-03 |
| HENRIQUES RICHARD C JR | director: | 2022-05-25 | A-Award | 0 | 2022-05-26 |
| BURGESS DANIEL D | director | 2022-05-25 | A-Award | 2.25 | 2022-05-26 |
| BURGESS DANIEL D | director: | 2022-05-25 | A-Award | 0 | 2022-05-26 |
| Meyers James R | director: | 2022-05-25 | A-Award | 0 | 2022-05-26 |
| Torti Frank | director | 2022-05-25 | A-Award | 2.25 | 2022-05-26 |
| Torti Frank | director: | 2022-05-25 | A-Award | 0 | 2022-05-26 |
| Tran Tram | director: | 2022-05-25 | A-Award | 0 | 2022-05-26 |
| MANCHESTER KEITH S | director: | 2022-05-25 | A-Award | 0 | 2022-05-26 |
| MANCHESTER KEITH S | director | 2022-05-25 | A-Award | 2.25 | 2022-05-26 |
| Collier William H. | director, officer: President and CEO | 2022-01-20 | A-Award | 2.81 | 2022-01-20 |
| HASTINGS DAVID C | officer: Chief Financial Officer | 2022-01-20 | A-Award | 2.81 | 2022-01-20 |
| Howard Elizabeth | officer: Chief Compliance Officer | 2022-01-20 | A-Award | 2.81 | 2022-01-20 |
| Sofia Michael J. | officer: Chief Scientific Officer | 2022-01-20 | A-Award | 2.81 | 2022-01-20 |
| Picchio Gaston | officer: Chief Development Officer | 2022-01-20 | A-Award | 2.81 | 2022-01-20 |
| McElhaugh Michael J. | officer: Chief Business Officer | 2022-01-20 | A-Award | 2.81 | 2022-01-20 |
| Sofia Michael J. | officer: Chief Scientific Officer | 2021-12-01 | S-Sale | 5.09 | 2021-12-03 |
| Tran Tram | director | 2021-11-09 | A-Award | 3.5 | 2021-11-12 |
| Tran Tram | director: | 2021-11-09 | 0 | 2021-11-12 |